Magnesium intake and all-cause mortality after stroke: a cohort study.

BACKGROUND: Population-based studies have shown that adequate magnesium intake is associated with a lower risk of stroke and all-cause mortality. Whether adequate magnesium intake is important for reducing all-cause mortality risk after stroke remains unclear. METHODS: We analyzed data from 917 patients with a self-reported history of stroke from the National Health and Nutrition Examination Survey (NHANES) 2007-2018. The total magnesium intake was calculated by summing the magnesium intake from dietary and dietary supplements, and then adjusting for total energy intake according to the nutrient density method. Mortality status was determined using public-use linked mortality files from 2019. Cox regression model and restricted cubic splines were used to explore the relationship between magnesium intake and all-cause mortality. RESULTS: The average total magnesium intake across all patients was 251.0 (184.5-336.5) mg/d, and 321 (70.2%) males and 339 (73.7%) females had insufficient magnesium intake. During a median follow-up period of 5.3 years, 277 deaths occurred. After fully adjusting for confounding factors, total magnesium intake levels were inversely associated with all-cause mortality risk (HR per 1-mg/(100 kcal*d) increase, 0.97; 95% CI, 0.94-1.00; p = 0.017). Participants with the highest quartile of total magnesium intake (≥ 18.5 mg/(100 kcal*d)) had a 40% reduction in all-cause mortality risk compared to those with the lowest quartile (≤ 12.0 mg/(100 kcal*d)) (HR, 0.60; 95% CI, 0.38-0.94; p = 0.024). Stratified analyses showed that this inverse association was statistically significant in those who were older, female, without hypertension, and had smoking, normal renal function, and adequate energy intake. Dietary magnesium intake alone might be not related to all-cause mortality. CONCLUSIONS: Stroke survivors who consumed adequate amounts of magnesium from diet and supplements had a lower risk of all-cause mortality.

Complete chloroplast genome data of Ranunculus membranaceus (Ranunculaceae), an important medicinal plant species.

The perennial alpine herb Ranunculus membranaceus (Ranunculaceae) has significant medicinal value. The complete chloroplast genome of R. membranaceus was sequenced by high-throughput Illumina sequencing Platform Illumina NovaSeq 6000. The circular genome is 156,028 bp in size, including two inverted repeats (IRs) of 25,361 bp, a large single-copy (LSC) region of 85,491 bp, and a small single-copy (SSC) region of 19,815 bp. A total of 128 genes were annotated, namely 84 protein-coding genes (PCGs), 36 tRNA genes, and eight rRNA genes. Two phylogenetic trees of 18 species of the tribe Ranunculeae species were constructed with Meconopsis punicea as the outgroup based on the whole chloroplast genomes and the concatenated sequence of PCGs, respectively. Phylogeny showed that R. membranaceus was closely related to R. yunnanensis. These data enrich knowledge of Ranunculaceae genetics and will contribute to further studies of R. membranaceus in molecular breeding, genetic transformation, species identification, genetic engineering and phylogenetic research.

Current and emerging biological therapy in adult-onset Still's disease.

Adult-onset Still's disease (AOSD) is a rare, but characteristic non-familial, multi-genic systemic auto-inflammatory disorder, characterized by high spiking fever, salmon-like evanescent skin rash, polyarthritis, sore throat, hyperferritinemia and leucocytosis. The hallmark of AOSD is a cytokine storm triggered by dysregulation of inflammation. Nowadays, with advances in anti-cytokine biologic agents, the treatment of AOSD is no longer limited to NSAIDs, glucocorticoids or conventional synthetic DMARDs. In this review, we focussed on the roles of these cytokines in the pathogenesis of AOSD and summarized the current and emerging biological therapy.